LATEST ANNOUNCEMENT

CMS (867.HK/8A8.SG): Innovative Drug Lumirix(R) Approved in China for Additional Indication of Atopic Dermatitis (AD)

SHENZHEN, CHINA - China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that its subsidiary, Dermavon Holdings Limited ("Dermavon", an innovative pharmaceutical company specialized in skin health which is applying for a...